Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	25.31	41.72	27.39	140.6	184.44	39.3
Short-Term Investments	114.86	119.08	220.92	130.58	177.69	68.86
Cash & Short-Term Investments	140.16	160.8	248.31	271.18	362.13	108.15
Cash Growth	-37.97%	-35.24%	-8.43%	-25.11%	234.83%	-
Accounts Receivable	-	0.31	1.26	2.45	-	-
Other Receivables	-	-	-	-	1.27	-
Total Trade Receivables	-	0.31	1.26	2.45	1.27	-
Other Current Assets	4.4	4.43	8.4	4.64	3.49	0.76
Total Current Assets	144.56	165.54	257.96	278.27	366.9	108.92
Net Property, Plant & Equipment	44.92	47.38	57.66	65.15	33.26	21.89
Long-Term Investments	2.15	2.15	3.45	10.68	7.81	6.42
Other Long-Term Assets	5.32	6.03	5.54	10.74	6.52	4.77
Total Assets	196.95	221.1	324.6	364.84	414.49	141.99
Accounts Payable	2.4	1.49	0.53	1.79	2.01	1.35
Accrued Expenses	4.69	6.72	8.42	11.47	8.79	3.53
Current Portion of Leases	6.11	6.03	5.59	3.43	1.52	0.69
Unearned Revenue	9.31	8.7	22.76	48.91	34.69	19.6
Other Current Liabilities	-	-	-	3.27	1.54	-
Total Current Liabilities	22.5	22.93	37.31	68.86	48.54	25.17
Long-Term Debt	-	-	-	-	-	30.28
Long-Term Leases	33.08	34.63	40.19	44.8	17.06	17.97
Other Long-Term Liabilities	3.59	4.94	12.25	36.01	77.22	24.63
Total Long-Term Liabilities	36.67	39.57	52.43	80.81	94.27	72.87
Total Liabilities	59.17	62.51	89.74	149.67	142.81	98.04
Common Stock	0	0	0	-	0.03	0.03
Additional Paid-in Capital	471.75	469.2	457.15	9.46	2.51	0.55
Accumulated Other Comprehensive Income	-0.04	0.26	0.71	-0.1	-0.27	-0.02
Retained Earnings	-333.93	-310.87	-223	-144.94	-76.69	-33.1
Total Common Shareholders' Equity	137.79	158.6	234.86	-135.58	-74.43	-32.54
Minority Interest	-	-	-	350.76	346.1	76.5
Shareholders' Equity	137.79	158.6	234.86	215.17	271.68	43.95
Total Liabilities & Equity	196.95	221.1	324.6	364.84	414.49	141.99
Total Debt	39.19	40.66	45.78	48.23	18.57	48.93
Net Cash (Debt)	100.98	120.14	202.53	222.95	343.56	59.23
Net Cash Growth	-15.95%	-40.68%	-9.16%	-35.10%	480.08%	-
Net Cash Per Share	2.70	3.23	6.13	65.49	101.06	17.40
Book Value	137.79	158.6	234.86	-135.58	-74.43	-32.54
Book Value Per Share	3.69	4.26	7.11	-39.82	-21.89	-9.56
Tangible Book Value	137.79	158.6	234.86	-135.58	-74.43	-32.54
Tangible Book Value Per Share	3.69	4.26	7.11	-39.82	-21.89	-9.56

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q